ACXP

Acurx Pharmaceuticals, Inc. [ACXP] Stock Forecast

Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000

ACXP Stock Summary

Top 10 Correlated ETFs

ACXP

Top 10 Correlated Stocks

ACXP

In the News

ACXP Financial details

Company Rating
-
Market Cap
25.61M
Income
-14.58M
Revenue
0
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
4
Optionable
No
Shortable
Yes
Earnings
10 May 2024
P/E
-7.73
Forward P/E
-
PEG
-28.86
P/S
-
P/B
14.61
P/C
-
P/FCF
-8.57
Quick Ratio
2.19
Current Ratio
2.22
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-1.15
EPS next Y
-
EPS next Q
-
EPS this Y
2.68%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
58.33%
-
-
-
-
SMA20
-12.61%
SMA50
-59.96%
SMA100
-43.01%
Inst Own
-
Inst Trans
-
ROA
-104%
ROE
-131%
ROC
-879.31%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
1.17-8.82
52W High
-46.13%
52W Low
+331%
RSI
39.13
Rel Volume
0.08
Avg Volume
159.98K
Volume
12.85K
Perf Week
4.11%
Perf Month
-33.9%
Perf Quarter
-49.11%
Perf Half Y
-53.66%
-
-
-
-
Beta
-1.897
-
-
Volatility
0.14%, 0.51%
Prev Close
0.94%
Price
4.31
Change
7.21%

Something similar

Top by Market Cap
BRK-A
LLY
BRH.DE
META
ABEA.DE
Top Correlated ETFs
DGZ
GLL
Top Correlated Stocks
MPVDF
PRTC
ANX.L
CWR.L
CELU
Similar Market Cap
SMWN.DE
INO-UN.TO
8153.HK
GSMFX
3DES.L

Company Profile

Healthcare Biotechnology
  • Volume Average 159.98K
  • Market Capitalization 25.61M
  • Employee 4
  • CEO Mr. David P. Luci CPA, Esq., J.D.
  • Headquarters Staten Island,NY,US
  • IPO Date 2021-06-25
  • Website https://www.acurxpharma.com

Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. Its lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that has completed Phase II clinical trial to treat patients with clostridium difficile infections. The company is also developing ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus, vancomycin-resistant enterococcus, and penicillin-resistant streptococcus pneumoniae. Acurx Pharmaceuticals, Inc. was incorporated in 2017 and is headquartered in Staten Island, New York.